Company Profile
Belite Bio Stock Price, News & Analysis
- Ticker:
- BLTE
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States with global ties
Stock performance
160.67 USD (+1.37%)
Close
Last updated: August 6, 2026
5.41B USD
Market cap
Why the stock is moving
The latest company update was “Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results”. BLTE changed 1.37% and closed at $160.67 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this earnings update.
Company overview
Retinal Degeneration Company
Belite Bio develops therapies for Stargardt disease type 1, geographic atrophy secondary to advanced dry age-related macular degeneration, and selected metabolic disorders. Lead candidate tinlarebant is an oral therapy designed to reduce the accumulation of bisretinoid toxins in the eye.
Tinlarebant Development Program
Tinlarebant has completed the adolescent STGD1 Phase 3 DRAGON trial and continues to be evaluated in DRAGON II, which includes a Japanese Phase 1b component and a global Phase 2/3 study, as well as the Phase 3 PHOENIX study in geographic atrophy. The company is preparing for potential STGD1 commercialization.
Oral Retinoid Modulation Strategy
Tinlarebant is designed to reduce delivery of retinol to the eye and thereby limit formation of toxic bisretinoid byproducts. This mechanism supports development in inherited Stargardt disease and the larger geographic atrophy population.
Regulatory and Geographic Expansion
Belite has initiated a rolling U.S. NDA submission for tinlarebant in STGD1 and received Swissmedic Orphan Drug Status. The inclusion of Japanese patients in DRAGON II is intended to support a potential future NDA in Japan.
Commercial Preparation
With the adolescent Phase 3 program completed and the U.S. submission underway, Belite is moving from clinical development toward launch planning in STGD1. The geographic atrophy program could subsequently expand the addressable market beyond inherited retinal disease.
Future catalysts
Completion of the rolling NDA submission for tinlarebant in STGD1 was expected in the second quarter of 2026.
The 530-patient Phase 3 PHOENIX study in geographic atrophy is fully enrolled, with an interim analysis planned.
Japanese and global data from DRAGON II are expected to support a potential Japanese NDA and additional regional filings.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Belite Bio (BLTE)?
Belite Bio (BLTE) most recently closed at 160.67 USD, a +1.37% move versus the previous session.
What is the market cap of Belite Bio (BLTE)?
Belite Bio currently has a market capitalization of 5.41B USD on BioPharmSignal.
What does Belite Bio do?
Retinal Degeneration Company Belite Bio develops therapies for Stargardt disease type 1, geographic atrophy secondary to advanced dry age-related macular degeneration, and selected metabolic disorders. Lead candidate tinlarebant is an oral therapy designed to reduce the accumulation of bisretinoid toxins in the eye. Tinlarebant Development...
On which exchange is BLTE stock listed?
Belite Bio (BLTE) is associated with NASDAQ, United States with global ties, Biopharma.
What is Retinal?
Retinal Degeneration Company Belite Bio develops therapies for Stargardt disease type 1, geographic atrophy secondary to advanced dry age-related macular degeneration, and selected metabolic disorders.
Which conditions is Belite Bio targeting with Retinal?
Belite Bio is associated with metabolic disease based on its company overview and current catalyst commentary.
How does Belite Bio describe recent progress with Retinal?
Completion of the rolling NDA submission for tinlarebant in STGD1 was expected in the second quarter of 2026. The 530-patient Phase 3 PHOENIX study in geographic atrophy is fully enrolled, with an interim analysis planned. Japanese and global data from DRAGON II are expected to support a potential Japanese NDA and additional regional filings.
What is Degeneration?
Retinal Degeneration Company Belite Bio develops therapies for Stargardt disease type 1, geographic atrophy secondary to advanced dry age-related macular degeneration, and selected metabolic disorders.